Answers are grounded in this paper and cite their sources.
Background: The plasminogen activator inhibitor-1 (PAI-1) is a puissant antifibrinolytic factor; plasma PAI-1 level is high in type 2 diabetes. 4G/5G polymorphism of PAI-1 gene is a major genetic determinant of plasma PAI-1 levels, with 4G carriers having high PAI-1 level than 5G, theses pose the question about relation T2 patients and those polymorphisms. The aim of this study was to determine the relationship between the polymorphisms −675 4G/5G and −844 G/A of PAI-1 gene and type 2 diabetes mellitus. Methods: A case control study of 491 diabetic and 400 healthy controls. Genotyping of the polymorphism −675 4G/5G was done by PCR-ASA (polymerase chain reaction, allele specific amplification), and the polymorphism −844 G/A was done with PCR-RFLP (restriction fragment length polymorphism), the allelic frequency is calculated with hardy-Weinberg law, the statistic analysis was done by SPSS version 10. Results: Higher frequencies of The genotypes 4G/4G (p = 0.01) and 4G/5G of polymorphism −675 4G/5G were seen in diabetic (p = 0.05) and higher frequencies of 5G/5G was seen in controls (p −844 G/A was seen in diabetics and G/G was seen in controls (p = 0.01). Conclusion: Our study found association between 4G allele of −675 4G/5G and A allele of −844 G/A of PAI-1 gene and having type 2 diabetes mellitus in Tunisian population.
No takes yet. Share an insight, caveat, or question.
Moustapha et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: